Arkell Thomas R, Abelev Sarah V, Mills Llewellyn, Suraev Anastasia, Arnold Jonathon C, Lintzeris Nicholas, McGregor Iain S
Centre for Mental Health and Brain Science, Swinburne University of Technology, Melbourne, VIC, Australia.
Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia.
J Cannabis Res. 2023 Sep 6;5(1):35. doi: 10.1186/s42238-023-00202-y.
Road safety is an important concern amidst expanding worldwide access to legal cannabis. The present study reports on the driving-related subsection of the Cannabis as Medicine Survey 2020 (CAMS-20) which surveyed driving-related behaviors, attitudes, and perceptions among Australian medical cannabis (MC) users. Of the 1063 respondents who reported driving a motor vehicle in the past 12 months, 28% (297/1063) reported driving under the influence of cannabis (DUIC). Overall, 49-56% of respondents said they typically drive within 6 h of MC use, depending on the route of administration (oral or inhaled). Non-medical cannabis (NMC) was perceived to be more impairing for driving than MC. Binary logistic regression revealed associations between likelihood of DUIC and (1) inhaled routes of cannabis administration, (2) THC-dominant products, (3) illicit rather than prescribed use, (4) believing NMC does not impair driving, and (5) not being deterred by roadside drug testing. Overall, these findings suggest there is a relatively low perception of driving-related risk among MC users. Targeted education programs may be needed to highlight the potential risks associated with DUIC, and further research is needed to determine whether driving performance is differentially affected by MC and NMC.
在全球合法大麻使用日益普及的背景下，道路安全成为一个重要问题。本研究报告了《2020年大麻作为药物调查》（CAMS - 20）中与驾驶相关的部分，该调查针对澳大利亚医用大麻（MC）使用者的驾驶相关行为、态度和认知进行了调查。在过去12个月中报告驾驶机动车的1063名受访者中，28%（297/1063）报告在大麻影响下驾驶（DUIC）。总体而言，49 - 56%的受访者表示，根据给药途径（口服或吸入），他们通常在使用医用大麻后6小时内开车。非医用大麻（NMC）被认为比医用大麻对驾驶的影响更大。二元逻辑回归揭示了DUIC可能性与以下因素之间的关联：（1）大麻吸入给药途径；（2）以四氢大麻酚（THC）为主的产品；（3）非法使用而非处方使用；（4）认为非医用大麻不会影响驾驶；（5）不受路边药物检测的威慑。总体而言，这些发现表明医用大麻使用者对与驾驶相关风险的认知相对较低。可能需要有针对性的教育项目来强调与DUIC相关的潜在风险，并且需要进一步研究以确定驾驶性能是否受到医用大麻和非医用大麻的不同影响。
